QT Prolongation Risks in HFpEF: The Next Frontier in Cardiotoxicity
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Heart failure with preserved ejection fraction (HFpEF) has emerged as the predominant phenotype of heart failure globally, largely due to aging populations and the rise in cardiometabolic diseases. Once considered primarily a mechanically driven disorder characterized by impaired ventricular relaxation, HFpEF is now understood as a complex multisystem syndrome encompassing structural, metabolic, inflammatory, and electrophysiological abnormalities. Among these emerging aspects, QT interval prolongation has garnered significant clinical attention as an indicator of delayed ventricular repolarization and arrhythmic vulnerability. QT prolongation is an integrated manifestation of myocardial remodeling, autonomic imbalance, ion channel dysfunction, electrolyte disturbances, and pharmacological exposure. Increasing clinical evidence indicates that patients with HFpEF exhibit heightened susceptibility to both spontaneous and drug-induced QT prolongation compared to individuals without heart failure. Despite preserved systolic function, these patients frequently experience ventricular arrhythmias and sudden cardiac death. This comprehensive review synthesizes current mechanistic, clinical, and pharmacological evidence linking HFpEF to QT prolongation. Particular emphasis is placed on electrophysiological remodeling, microvascular disease, polypharmacy, monitoring strategies, precision medicine approaches, and the expanding role of clinical pharmacists in cardiotoxicity prevention[1, 2].
Fields of Study & Subjects
Cardiac electrophysiology and arrhythmias
Cardiac pacing and defibrillation studies
Heart Failure Treatment and Management
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 27 March 2026
- Language
- EN